| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
338 |
325 |
$0.00 |
| 82540 |
|
648 |
634 |
$0.00 |
| 3051F |
|
145 |
145 |
$0.00 |
| 80061 |
Lipid panel |
1,670 |
1,663 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
653 |
339 |
$0.00 |
| 83540 |
|
508 |
499 |
$0.00 |
| 98966 |
|
16 |
15 |
$0.00 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
109 |
109 |
$0.00 |
| 77062 |
|
94 |
94 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,287 |
2,463 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12 |
12 |
$0.00 |
| 90750 |
|
160 |
160 |
$0.00 |
| 3077F |
|
443 |
422 |
$0.00 |
| 80076 |
|
201 |
198 |
$0.00 |
| 3078F |
|
1,577 |
1,437 |
$0.00 |
| 82274 |
|
353 |
353 |
$0.00 |
| 86703 |
|
544 |
541 |
$0.00 |
| 82570 |
|
282 |
268 |
$0.00 |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
308 |
201 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
75 |
75 |
$0.00 |
| 3046F |
|
120 |
119 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
58 |
27 |
$0.00 |
| 85610 |
|
573 |
418 |
$0.00 |
| 84100 |
|
327 |
230 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
115 |
114 |
$0.00 |
| 99442 |
|
58 |
56 |
$0.00 |
| 86480 |
|
229 |
227 |
$0.00 |
| 86705 |
|
91 |
89 |
$0.00 |
| 84155 |
|
15 |
12 |
$0.00 |
| 81003 |
|
52 |
52 |
$0.00 |
| 90661 |
|
19 |
19 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
47 |
46 |
$0.00 |
| 84439 |
|
62 |
59 |
$0.00 |
| 97161 |
|
24 |
24 |
$0.00 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
49 |
37 |
$0.00 |
| 82565 |
|
13 |
13 |
$0.00 |
| 90653 |
|
35 |
35 |
$0.00 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
29 |
29 |
$0.00 |
| 85007 |
|
31 |
24 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
16 |
14 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
82 |
52 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14 |
13 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,246 |
1,112 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
2,821 |
2,282 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,076 |
2,058 |
$0.00 |
| 3075F |
|
400 |
385 |
$0.00 |
| 87522 |
Neg quan hep c or qual rna |
509 |
507 |
$0.00 |
| 83735 |
|
1,203 |
807 |
$0.00 |
| 81001 |
|
442 |
410 |
$0.00 |
| 82043 |
|
648 |
634 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,698 |
2,233 |
$0.00 |
| 3074F |
|
1,104 |
1,010 |
$0.00 |
| 90656 |
|
121 |
121 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,327 |
2,263 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
400 |
266 |
$0.00 |
| 85652 |
|
265 |
254 |
$0.00 |
| 85027 |
|
647 |
584 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
162 |
147 |
$0.00 |
| 86780 |
|
157 |
156 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
823 |
807 |
$0.00 |
| 90686 |
|
108 |
108 |
$0.00 |
| 82607 |
|
382 |
375 |
$0.00 |
| 86141 |
|
301 |
297 |
$0.00 |
| 3079F |
|
299 |
287 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
5,677 |
4,508 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
942 |
932 |
$0.00 |
| 97010 |
|
211 |
116 |
$0.00 |
| 3052F |
|
28 |
28 |
$0.00 |
| 86706 |
|
149 |
148 |
$0.00 |
| 83550 |
|
504 |
495 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
779 |
773 |
$0.00 |
| 3044F |
|
568 |
565 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
75 |
75 |
$0.00 |
| 99443 |
|
22 |
19 |
$0.00 |
| 92227 |
|
13 |
13 |
$0.00 |
| 82746 |
|
193 |
188 |
$0.00 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
93 |
53 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
77 |
76 |
$0.00 |
| 85730 |
|
53 |
42 |
$0.00 |
| 87340 |
|
109 |
108 |
$0.00 |
| 82728 |
|
530 |
520 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
81 |
52 |
$0.00 |
| 3080F |
|
86 |
83 |
$0.00 |
| 1111F |
|
260 |
247 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
47 |
43 |
$0.00 |
| 84153 |
|
18 |
16 |
$0.00 |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
37 |
37 |
$0.00 |
| 85008 |
|
27 |
26 |
$0.00 |
| 92250 |
|
16 |
16 |
$0.00 |
| 99441 |
|
14 |
13 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
12 |
12 |
$0.00 |
| 1220F |
|
14 |
14 |
$0.00 |